SK284250B6 - Kompozícia znižujúca cholesterol, jej použitie a terapeuticky účinný produkt s jej obsahom - Google Patents
Kompozícia znižujúca cholesterol, jej použitie a terapeuticky účinný produkt s jej obsahom Download PDFInfo
- Publication number
- SK284250B6 SK284250B6 SK415-97A SK41597A SK284250B6 SK 284250 B6 SK284250 B6 SK 284250B6 SK 41597 A SK41597 A SK 41597A SK 284250 B6 SK284250 B6 SK 284250B6
- Authority
- SK
- Slovakia
- Prior art keywords
- cholesterol
- composition
- forbes
- phytosterols
- phytosterol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 97
- 239000000344 soap Substances 0.000 title abstract description 23
- 238000004537 pulping Methods 0.000 title abstract 3
- 229930182558 Sterol Natural products 0.000 title description 23
- 150000003432 sterols Chemical class 0.000 title description 23
- 235000003702 sterols Nutrition 0.000 title description 23
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 215
- 235000012000 cholesterol Nutrition 0.000 claims description 81
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 55
- LGJMUZUPVCAVPU-JFBKYFIKSA-N Sitostanol Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC2)CC1 LGJMUZUPVCAVPU-JFBKYFIKSA-N 0.000 claims description 35
- LGJMUZUPVCAVPU-HRJGVYIJSA-N stigmastanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]2(C)CC1 LGJMUZUPVCAVPU-HRJGVYIJSA-N 0.000 claims description 35
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 20
- 201000001320 Atherosclerosis Diseases 0.000 claims description 16
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 claims description 15
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims description 15
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 claims description 15
- 235000000431 campesterol Nutrition 0.000 claims description 15
- 229950005143 sitosterol Drugs 0.000 claims description 15
- 229940076810 beta sitosterol Drugs 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 7
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 6
- 150000001298 alcohols Chemical class 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002894 organic compounds Chemical class 0.000 claims description 2
- 150000003648 triterpenes Chemical class 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 19
- 239000002244 precipitate Substances 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 7
- 235000005911 diet Nutrition 0.000 description 49
- 230000000694 effects Effects 0.000 description 46
- 229940068065 phytosterols Drugs 0.000 description 44
- 241000699800 Cricetinae Species 0.000 description 42
- 108010010234 HDL Lipoproteins Proteins 0.000 description 38
- 102000015779 HDL Lipoproteins Human genes 0.000 description 38
- 230000000378 dietary effect Effects 0.000 description 31
- 239000003784 tall oil Substances 0.000 description 30
- 235000013305 food Nutrition 0.000 description 23
- 235000010469 Glycine max Nutrition 0.000 description 22
- 244000068988 Glycine max Species 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 19
- 230000037213 diet Effects 0.000 description 18
- VGSSUFQMXBFFTM-UHFFFAOYSA-N (24R)-24-ethyl-5alpha-cholestane-3beta,5,6beta-triol Natural products C1C(O)C2(O)CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 VGSSUFQMXBFFTM-UHFFFAOYSA-N 0.000 description 16
- 230000007423 decrease Effects 0.000 description 14
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 101100055841 Danio rerio apoa1 gene Proteins 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 11
- 239000002023 wood Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 238000004817 gas chromatography Methods 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 235000012631 food intake Nutrition 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 108010007622 LDL Lipoproteins Proteins 0.000 description 7
- 102000007330 LDL Lipoproteins Human genes 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 235000002378 plant sterols Nutrition 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 238000008214 LDL Cholesterol Methods 0.000 description 6
- 102000004895 Lipoproteins Human genes 0.000 description 6
- 108090001030 Lipoproteins Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- 150000002430 hydrocarbons Chemical class 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 6
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 5
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 5
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000016831 stigmasterol Nutrition 0.000 description 5
- 229940032091 stigmasterol Drugs 0.000 description 5
- 101150102415 Apob gene Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 235000014590 basal diet Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000001906 cholesterol absorption Effects 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 235000021004 dietary regimen Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 3
- 229960003132 halothane Drugs 0.000 description 3
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- ARYTXMNEANMLMU-UHFFFAOYSA-N 24alpha-methylcholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(C)C(C)C)C1(C)CC2 ARYTXMNEANMLMU-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 235000019759 Maize starch Nutrition 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- ARYTXMNEANMLMU-ATEDBJNTSA-N campestanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]2(C)CC1 ARYTXMNEANMLMU-ATEDBJNTSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- KZJWDPNRJALLNS-FBZNIEFRSA-N clionasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-FBZNIEFRSA-N 0.000 description 2
- 235000020940 control diet Nutrition 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000000871 hypocholesterolemic effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- TYWMIZZBOVGFOV-UHFFFAOYSA-N tetracosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCO TYWMIZZBOVGFOV-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 description 1
- INDVLXYUCBVVKW-PXBBAZSNSA-N 24-methylenecholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCC(=C)C(C)C)[C@@]1(C)CC2 INDVLXYUCBVVKW-PXBBAZSNSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 102000018619 Apolipoproteins A Human genes 0.000 description 1
- 108010027004 Apolipoproteins A Proteins 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- BDCFUHIWJODVNG-UHFFFAOYSA-N Desmosterol Natural products C1C=C2CC(O)C=CC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 BDCFUHIWJODVNG-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 101000687448 Homo sapiens REST corepressor 1 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 206010061274 Malocclusion Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- HCXVJBMSMIARIN-LWINXXIXSA-N Poriferasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C HCXVJBMSMIARIN-LWINXXIXSA-N 0.000 description 1
- 102100024864 REST corepressor 1 Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 240000003021 Tsuga heterophylla Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- -1 aliphatic alcohols Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- HVYWMOMLDIMFJA-CHMPPTJKSA-N cholesterol-4-13c Chemical compound C1C=C2[13CH2][C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-CHMPPTJKSA-N 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000011365 complex material Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- AVSXSVCZWQODGV-DPAQBDIFSA-N desmosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 AVSXSVCZWQODGV-DPAQBDIFSA-N 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011121 hardwood Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000002655 kraft paper Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000004903 negative regulation of intestinal cholesterol absorption Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000001422 normality test Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- LGJMUZUPVCAVPU-KZXGMYDKSA-N stigmastanol Chemical compound C1CC2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 LGJMUZUPVCAVPU-KZXGMYDKSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Detergent Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fats And Perfumes (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Manufacture Of Tobacco Products (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31494594A | 1994-09-29 | 1994-09-29 | |
| PCT/CA1995/000555 WO1996010033A1 (fr) | 1994-09-29 | 1995-09-29 | Compositions de sterols obtenues a partir du savon issu de la trituration de la pate a papier |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK41597A3 SK41597A3 (en) | 1997-11-05 |
| SK284250B6 true SK284250B6 (sk) | 2004-12-01 |
Family
ID=23222178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK415-97A SK284250B6 (sk) | 1994-09-29 | 1995-09-29 | Kompozícia znižujúca cholesterol, jej použitie a terapeuticky účinný produkt s jej obsahom |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US5770749A (fr) |
| EP (3) | EP1707572B1 (fr) |
| JP (1) | JPH10506394A (fr) |
| CN (1) | CN1057768C (fr) |
| AT (1) | ATE216395T1 (fr) |
| AU (1) | AU3559795A (fr) |
| BG (1) | BG64054B1 (fr) |
| BR (1) | BR9509119A (fr) |
| CA (1) | CA2201328A1 (fr) |
| CZ (1) | CZ298622B6 (fr) |
| DE (1) | DE69526442T3 (fr) |
| DK (2) | DK1707572T3 (fr) |
| EE (1) | EE9700073A (fr) |
| ES (2) | ES2464465T3 (fr) |
| GE (1) | GEP20022657B (fr) |
| HU (1) | HUT77522A (fr) |
| LT (1) | LT4305B (fr) |
| LV (1) | LV11900B (fr) |
| MD (1) | MD1721C2 (fr) |
| MX (1) | MX9702308A (fr) |
| NO (2) | NO310293B1 (fr) |
| NZ (1) | NZ293210A (fr) |
| PL (1) | PL186441B1 (fr) |
| PT (1) | PT783514E (fr) |
| RU (1) | RU2165431C2 (fr) |
| SK (1) | SK284250B6 (fr) |
| TJ (1) | TJ302B (fr) |
| WO (1) | WO1996010033A1 (fr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965449A (en) * | 1996-07-03 | 1999-10-12 | Forbes Medi-Tech, Inc. | Method of assessing risk for cardiovascular disease and other disorders and phytosterol-based compositions useful in preventing and treating cardiovascular disease and other disorders |
| US6139872A (en) * | 1996-08-14 | 2000-10-31 | Henkel Corporation | Method of producing a vitamin product |
| US5985936A (en) * | 1997-12-18 | 1999-11-16 | Forbes Medi-Tech, Inc. | Method of preventing and delaying onset of Alzheimer's disease and composition therefor |
| US5952393A (en) * | 1998-02-12 | 1999-09-14 | Sorkin, Jr.; Harlan Lee | Composition for reducing serum cholesterol levels |
| US6110502A (en) * | 1998-02-19 | 2000-08-29 | Mcneil-Ppc, Inc. | Method for producing water dispersible sterol formulations |
| BR9910950A (pt) * | 1998-06-05 | 2002-02-13 | Forbes Medi Tech Inc | Composições compreendendo fitosterol e fitostanol tendo solubilidade e dispersibilidade aumentadas |
| CA2346881A1 (fr) | 1998-07-20 | 2000-02-03 | Egon Novak | Compositions a base de phytosterol, phytostanol ou de melange des deux, et d'acides gras .omega.-3 ou de certains de leurs derives, utilisation preventive ou curative de cette composition contre des affections cardio-vasculaires et autres troubles |
| US6242001B1 (en) | 1998-11-30 | 2001-06-05 | Mcneil-Ppc, Inc. | Method for producing dispersible sterol and stanol compounds |
| DE19916034C1 (de) * | 1999-04-09 | 2000-08-03 | Cognis Deutschland Gmbh | Verfahren zur Gewinnung von Phytosterinen |
| BR0010045A (pt) * | 1999-04-27 | 2002-03-12 | Sterol Technologies Ltd | Método de extração e isolamento |
| JP2002543088A (ja) * | 1999-04-27 | 2002-12-17 | フォーブス メディ−テック インコーポレーテッド | 木材または植物由来供給源からのフィトステロールの精製方法、およびそれから生じる組成物 |
| US6770767B1 (en) * | 1999-04-27 | 2004-08-03 | Sterol Techologies Ltd. | Method for the extraction and isolation of neutral substances from a soap |
| FI991533A (fi) * | 1999-07-05 | 2001-01-06 | Sohkar Oy | Menetelmä orgaanisten aineiden käsittelemiseksi |
| US6998501B1 (en) | 1999-08-30 | 2006-02-14 | Ocean Nutrition Canada Limited | Nutritional supplement for lowering serum triglyceride and cholesterol levels |
| CA2382262C (fr) * | 1999-08-30 | 2004-12-07 | Ocean Nutrition Canada Ltd. | Supplement nutritionnel destine a abaisser le taux de cholesterol et de triglycerides seriques |
| US6197832B1 (en) | 1999-09-14 | 2001-03-06 | Harlan Lee Sorkin, Jr. | Composition for reducing serum cholesterol levels |
| NZ508692A (en) * | 1999-12-15 | 2002-10-25 | Mcneil Ppc Inc | Cholesterol lowering comestibles comprising policosanol (predominately octasanol) and sterol |
| US6355274B1 (en) | 1999-12-15 | 2002-03-12 | Mcneil-Ppc, Inc. | Encapsulated long chain alcohols |
| US7232574B1 (en) | 1999-12-15 | 2007-06-19 | Mcneil-Ppc, Inc. | Long chain alcohols provided in edible oils |
| US7147859B2 (en) * | 2000-05-15 | 2006-12-12 | Laboratorios Biosintetica Ltda. | Application of phytosterols (and their isomers), folic acid, cyanocobalamin and pyridoxin in dietetic (alimentary) fibers |
| BR0001794A (pt) * | 2000-05-15 | 2001-12-26 | Laboratorios Biosintetica Ltda | Aplicação de fitosteróides (e seus isÈmeros), ácidofólico, cianocobalamina e piridoxina em fibrasdietéticas (alimentares) |
| JP4707862B2 (ja) * | 2001-04-16 | 2011-06-22 | 花王株式会社 | 植物ステロールの製法 |
| WO2003009854A1 (fr) * | 2001-07-20 | 2003-02-06 | Lonza Ag | Composition hypolipidemiante contenant de la carnitine et du phytosterol |
| US7368138B2 (en) * | 2002-03-21 | 2008-05-06 | Archer-Daniels-Midland Company | Extraction of phytosterols from corn fiber using green solvents |
| CA2433246A1 (fr) * | 2003-06-25 | 2004-12-25 | Telum Technologies Inc. | Procede de recuperation de produits a valeur ajoutee a partir de savon a l'huile de pin |
| US8309156B2 (en) * | 2005-12-20 | 2012-11-13 | Pharmachem Laboratories, Inc. | Compositions comprising one or more phytosterols and/or phytostanols, or derivatives thereof, and high HLB emulsifiers |
| KR20080108969A (ko) * | 2005-12-20 | 2008-12-16 | 포비스 메디-테크 인코포레이티드 | 수성 상에 비에스테르화 파이토스테롤을 포함하는 에멀젼 |
| WO2007124597A1 (fr) * | 2006-05-01 | 2007-11-08 | Forbes Medi-Tech Inc. | Composition comprenant un ou plusieurs phytostérols et/ou phytostanols estérifiés dans lesquels sont solubilisés un ou plusieurs phytostérols et/ou phytostanols non estérifiés afin d'améliorer les bienfaits thérapeutiques et la formulation |
| US20070254026A1 (en) * | 2006-05-01 | 2007-11-01 | Forbes Medi-Tech Inc. | Softgel capsules |
| EP2036445A1 (fr) * | 2007-09-05 | 2009-03-18 | Dietetics Pharma S.r.l. | Préparation nutraceutique sous forme de poudre contenant des stérols d'origine végétale |
| US20110207952A1 (en) * | 2010-02-22 | 2011-08-25 | Rafael Avila | Cholesterol extraction from algae and preparation of vegan vitamin d3 |
| EA024619B1 (ru) * | 2014-11-21 | 2016-10-31 | Эльвин Гаджи оглы Керимли | ФРАКСИНОСТЕРИН - 24β-ЭТИЛХОЛЕСТА-20-КАРБОКСИ-6(7),8(9)-ДИЕН 3β-ОЛА И ЕГО ПРОИЗВОДНОЕ |
| SE540791C2 (en) | 2016-01-29 | 2018-11-13 | Stora Enso Oyj | Extraction of phytosterols |
| WO2017137908A1 (fr) | 2016-02-12 | 2017-08-17 | Stora Enso Oyj | Distillation de composés neutres à partir de savon à l'huile de pin |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2573891A (en) * | 1950-05-09 | 1951-11-06 | Pittsburgh Plate Glass Co | Recovery of sterols |
| US2715638A (en) * | 1953-07-28 | 1955-08-16 | American Cyanamid Co | Production of sterols from tall oil pitch |
| US2835682A (en) * | 1955-08-08 | 1958-05-20 | Swift & Co | Sterol recovery process |
| US3840570A (en) * | 1970-12-07 | 1974-10-08 | Procter & Gamble | Process for preparing sterols from tall oil pitch |
| SE417107B (sv) * | 1973-06-29 | 1981-02-23 | Bjarne Holmbom | Forfarande for foredling av sapor |
| US4044031A (en) * | 1976-07-02 | 1977-08-23 | Ake Allan Johansson | Process for the separation of sterols |
| US4208286A (en) † | 1977-11-03 | 1980-06-17 | Kauppi Pekka K | Sulphate soap skimming apparatus |
| US4153622A (en) * | 1978-05-18 | 1979-05-08 | Medipolar Oy | Process for the recovery of β-sitosterol |
| FI58333C (fi) * | 1978-10-27 | 1981-01-12 | Kaukas Ab Oy | Foerfarande foer framstaellning av under 5 vikt-% alfa2-sitosterol innehaollande beta-sitosterolkoncentrat |
| FI57956C (fi) * | 1978-12-12 | 1980-11-10 | Farmos Oy | Foerfarande foer isolering av beta-sitosterol med laog alfa-sitosterolhalt |
| FI59416C (fi) * | 1979-11-19 | 1981-08-10 | Farmos Oy | Foerfarande foer utvinning av beta-sitosterol ur en sterolblandning utvunnen fraon raosaopans neutralfraktion |
| FI63423C (fi) * | 1981-01-27 | 1983-06-10 | Farmos Oy | Foerfarande foer separering av beta-sitosterol fraon en sterolblandning utvunnen ur raosaopans neutralfraktion |
| JPS57206336A (en) * | 1981-06-12 | 1982-12-17 | Ajinomoto Co Inc | Edible oil |
| FI812279L (fi) * | 1981-07-21 | 1983-01-22 | Kaukas Ab Oy | Foerfarande foer rening av -sitosterol isolerad fraon neutralaemnet av sulfatcellulosaprocessens raosaopa |
| FI65440C (fi) * | 1981-07-21 | 1984-05-10 | Kaukas Ab Oy | Foerfarande foer separering av beta-sitosterol med en laog alfa-sitosterolhalt |
| JPS58116415A (ja) * | 1981-12-28 | 1983-07-11 | Riyoushiyoku Kenkyukai | コレステロ−ル低下剤の使用方法 |
| JPS6479119A (en) * | 1987-09-22 | 1989-03-24 | Daiichi Seiyaku Co | Drug of blended two components |
| FR2653974B1 (fr) * | 1989-11-03 | 1992-12-31 | Expanchimie Sarl | Additif alimentaire constitue d'extraits de soja et/ou d'avocat. |
| CA2028759A1 (fr) † | 1989-11-22 | 1991-05-23 | Jean-Marie Cassal | Steroides |
| RU2095367C1 (ru) * | 1991-05-03 | 1997-11-10 | Райсион Техтаат ой АБ | Вещество, понижающее уровень холестерина в сыворотке крови, и способ его получения |
| US5286845A (en) † | 1992-05-20 | 1994-02-15 | Union Camp Corporation | Acidification of tall oil soap using carbon dioxide |
-
1995
- 1995-09-29 TJ TJ97000458A patent/TJ302B/xx unknown
- 1995-09-29 EP EP05011507.0A patent/EP1707572B1/fr not_active Expired - Lifetime
- 1995-09-29 MD MD97-0178A patent/MD1721C2/ro unknown
- 1995-09-29 HU HU9702031A patent/HUT77522A/hu unknown
- 1995-09-29 EP EP01118776A patent/EP1148062A3/fr not_active Withdrawn
- 1995-09-29 SK SK415-97A patent/SK284250B6/sk unknown
- 1995-09-29 EP EP95932593A patent/EP0783514B2/fr not_active Expired - Lifetime
- 1995-09-29 EE EE9700073A patent/EE9700073A/xx unknown
- 1995-09-29 GE GEAP19953712A patent/GEP20022657B/en unknown
- 1995-09-29 RU RU97107020/04A patent/RU2165431C2/ru not_active IP Right Cessation
- 1995-09-29 DE DE69526442T patent/DE69526442T3/de not_active Expired - Lifetime
- 1995-09-29 PL PL95319384A patent/PL186441B1/pl not_active IP Right Cessation
- 1995-09-29 CZ CZ0092797A patent/CZ298622B6/cs not_active IP Right Cessation
- 1995-09-29 AT AT95932593T patent/ATE216395T1/de not_active IP Right Cessation
- 1995-09-29 CN CN95196307A patent/CN1057768C/zh not_active Expired - Fee Related
- 1995-09-29 ES ES05011507.0T patent/ES2464465T3/es not_active Expired - Lifetime
- 1995-09-29 JP JP8511228A patent/JPH10506394A/ja not_active Ceased
- 1995-09-29 NZ NZ293210A patent/NZ293210A/xx not_active IP Right Cessation
- 1995-09-29 DK DK05011507.0T patent/DK1707572T3/da active
- 1995-09-29 DK DK95932593T patent/DK0783514T4/da active
- 1995-09-29 PT PT95932593T patent/PT783514E/pt unknown
- 1995-09-29 CA CA002201328A patent/CA2201328A1/fr not_active Abandoned
- 1995-09-29 AU AU35597/95A patent/AU3559795A/en not_active Abandoned
- 1995-09-29 BR BR9509119A patent/BR9509119A/pt not_active IP Right Cessation
- 1995-09-29 WO PCT/CA1995/000555 patent/WO1996010033A1/fr active IP Right Grant
- 1995-09-29 ES ES95932593T patent/ES2173966T5/es not_active Expired - Lifetime
- 1995-09-29 MX MX9702308A patent/MX9702308A/es unknown
-
1996
- 1996-08-30 US US08/706,354 patent/US5770749A/en not_active Expired - Fee Related
-
1997
- 1997-03-20 NO NO19971304A patent/NO310293B1/no not_active IP Right Cessation
- 1997-03-25 BG BG101354A patent/BG64054B1/bg unknown
- 1997-04-23 LT LT97-074A patent/LT4305B/lt not_active IP Right Cessation
- 1997-04-28 LV LVP-97-78A patent/LV11900B/en unknown
-
2001
- 2001-03-01 NO NO20011062A patent/NO322293B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK284250B6 (sk) | Kompozícia znižujúca cholesterol, jej použitie a terapeuticky účinný produkt s jej obsahom | |
| US20060052351A1 (en) | Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of blood cholestrol and triglycerides and oxidative stress | |
| US6046184A (en) | Medicament for treating obesity and improving lipid metabolism | |
| JP2006516280A (ja) | 血漿コレステロール及びトリアシルグリセロールレベルを減少するためにスフィンゴ脂質を使用する方法 | |
| CA2486409A1 (fr) | Compositions de policosanol, extraites de nouvelles sources, et leurs utilisations | |
| WO1999029317A1 (fr) | Methodes et compositions de traitement du diabete | |
| Puel et al. | Black Lucques olives prevented bone loss caused by ovariectomy and talc granulomatosis in rats | |
| Park et al. | Influence of feeding β-Cyclodextrin to laying hens on the egg production and cholesterol content of egg yolk | |
| Rudzinska et al. | The influence of storage time and drying temperature on sterols content in seeds of rapeseed | |
| AU5939399A (en) | Sterol compositions from pulping soap | |
| AU2007200897B2 (en) | Sterol compositions from pulping soap | |
| US20210275486A1 (en) | Renal function maintenance and protection agent, and method for evaluating effect thereof | |
| KR100254528B1 (ko) | 대추추출물을포함하는콜레스테롤강하및콜레스테롤에스테르전이단백질저해용조성물 | |
| KR20170002392A (ko) | 7-하이드록시마타이레시놀을 포함하는 조성물 | |
| US20020086855A1 (en) | Medicament for treating obesity and improving lipid metabolism | |
| Bahgat et al. | Physical Exercise Versus Natural Estrogen Supplement in Treatment of Metabolic Syndrome in Aged Postmenopausal Wistar Rats | |
| Adaikpoh et al. | Changes in Some Serum and Heamatological Indices in Magnesium and Riboflavin Deficiency in Rats | |
| ESTERS | SUBSTANTIAL EQUIVALENCE NOTIFICATION | |
| KR20030082219A (ko) | 플라바논 에스테르 유도체 및 이를 포함하는 혈중 지질농도 관련 질환의 예방 및 치료용 조성물 |